Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
安斯泰来GLOW临床试验，即CLDN18.2阳性、HER2阴性的局部晚期不可切除或转移性胃癌和胃食管交界处癌的第二项III期试验，达到了无进展生存期（PFS）的
*本文来源于近期E药经理人对安斯泰来大中华区总经理滨口洋先生及其团队的专访，全文如下：...
安斯泰来SPOTLIGHT临床试验达到无进展生存期（PFS）的主要终点 详细数据将于未来召开的的学术会议上公布...
*本文来源于近期《CEO杂志》对安斯泰来大中华商业总经理滨口洋先生的专访，全文如下：...
2022年9月21日，由安斯泰来资助的四年期公益项目——安徽糖尿病视网膜病变（简称“糖网”）防治模式试点项目在合肥正式启动。该项目经安徽省卫
Follow China news
